Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22739002 | 0.94 | KRAS (0.31) | POLRMTKRASRIPK1 | |
| SCHEMBL20762571 | 0.92 | POLRMT (0.34) | POLRMTRIPK1TMPRSS2 | |
| SCHEMBL18666928 | 0.92 | POLRMT (0.34) | POLRMTRIPK1TMPRSS2 | |
| SCHEMBL18667331 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL22096278 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL18636470 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL18636467 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL18666874 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL20878382 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 | |
| SCHEMBL18636473 | 0.90 | CYP3A4 (0.39) | KRASRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3595672-B1 | COMPOUNDS FOR USE IN METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10682368-B2 | Methods of treating feline coronavirus infections | GILEAD SCIENCES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682368-B2 | Methods of treating feline coronavirus infections | SARS1, CPN1, CAT | POLRMT 36/4885KRAS 1893/4885RIPK1 2911/4885 |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | CAT, ACE, ACE2 | POLRMT 860/4885KRAS 1549/4885RIPK1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.